MEDA Pharma GmbH & Co. KG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Subsidiary
- Established
- 1919-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.medapharma.de
A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2022-02-07
- Lead Sponsor
- MEDA Pharma GmbH & Co. KG
- Target Recruit Count
- 45
- Registration Number
- NCT00189267
A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2022-02-07
- Lead Sponsor
- MEDA Pharma GmbH & Co. KG
- Target Recruit Count
- 72
- Registration Number
- NCT00189254
Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2022-02-07
- Lead Sponsor
- MEDA Pharma GmbH & Co. KG
- Target Recruit Count
- 128
- Registration Number
- NCT00189293
- Locations
- 🇮🇹
Unità Operativa di Ginecologia Oncologica, RCCS Ospedale Oncologico, Bari, Italy
🇮🇹Servizio Autonomo di Diagnosi Precoce dei Tumori Ginecologici Ospedale Vittorio Emanuele, Catania, Italy
🇮🇹Clinica Ostetrica Ginecologica, Ospedale Careggi, Firenze, Italy
5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-07-18
- Last Posted Date
- 2022-02-11
- Lead Sponsor
- MEDA Pharma GmbH & Co. KG
- Target Recruit Count
- 2418
- Registration Number
- NCT00120523
- Locations
- 🇺🇸
Children's Skin Center, Miami, Florida, United States
🇺🇸Dermatology Research Associates, Cincinnati, Ohio, United States
🇩🇪Novartis, Investigative Site, Germany
© Copyright 2024. All Rights Reserved by MedPath